Bottom line
XBI vs RYOIX: the short answer
XBI (State Street(R) SPDR(R) S&P(R) Biotech ETF) and RYOIX (Biotechnology Fund) are quite different portfolios: only about 15% of their top holdings (by weight) are shared.
But XBI is far broader, holding 161 positions to 74 for RYOIX, so beyond the top names it adds exposure RYOIX doesn't have.
XBI is cheaper at 0.35% vs 1.38% — a difference of $103 a year per $10,000 invested.
Over five years, RYOIX returned +4.0% a year vs −2.7% for XBI.
Updated Nov 19, 2026
XBI vs RYOIX side by side
| XBI | RYOIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Guggenheim |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 1.38% |
| Annual cost per $10k | $35 | $138 |
| 10-yr cost on $10k (prospectus) | $443 | $1,709 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +35.8% | +30.7% |
| 5-yr return (annualized) | −2.7% | +4.0% |
| 10-yr return (annualized) | +5.8% | +5.9% |
| Best quarter | +44.4% | +28.3% |
| Worst quarter | −26.2% | −22.5% |
| Net assets (fund) | $10.7B | $136.8M |
| Number of holdings | 161 | 74 |
| Portfolio turnover | 71% | 75% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XBI | RYOIX | Difference |
|---|---|---|---|
| 2025 | +35.8% | +30.7% | +5.1% |
| 2024 | +1.1% | −0.7% | +1.8% |
| 2023 | +7.5% | +6.1% | +1.4% |
| 2022 | −25.8% | −13.1% | −12.7% |
| 2021 | −20.5% | +1.8% | −22.3% |
| 2020 | +48.2% | +22.1% | +26.1% |
| 2019 | +32.2% | +25.0% | +7.2% |
| 2018 | −14.9% | −9.0% | −5.9% |
| 2017 | +43.7% | +29.7% | +13.9% |
| 2016 | −15.4% | −19.5% | +4.1% |
Source: Fund prospectus bar charts
Holdings overlap
5 of XBI's top 25 holdings also appear in RYOIX's top 25.
| Holding | XBI | RYOIX |
|---|---|---|
| Moderna Inc | 1.41% | 2.15% |
| Revolution Medicines Inc | 1.20% | 2.48% |
| Cytokinetics Inc | 1.18% | 1.35% |
| Natera Inc | 1.16% | 2.12% |
| Roivant Sciences Ltd | 1.16% | 1.66% |
Source: SEC Form N-PORT
XBI top 10
- State Street Global Advisors — 5.87%
- Apogee Therapeutics Inc — 1.49%
- Moderna Inc — 1.41%
- Twist Bioscience Corp — 1.41%
- Oruka Therapeutics Inc — 1.38%
- Kymera Therapeutics Inc — 1.36%
- Viking Therapeutics Inc — 1.30%
- Praxis Precision Medicines Inc — 1.29%
- Erasca Inc — 1.27%
- Revolution Medicines Inc — 1.20%
RYOIX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FAQ
What is the difference between XBI and RYOIX?
Which is cheaper, XBI or RYOIX?
Should I own both XBI and RYOIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.